177 Lutetium PSMA Therapy for Metastatic Prostate Cancer | Minute Medical, Vienna

At Minute Medical in Vienna, Austria, we have reimagined the treatment of metastatic prostate cancer by moving away from the "scattershot" approach of traditional radiation. Our center specializes in 177-Lutetium (Lu-177) PSMA therapy, a highly targeted radioligand therapy. While chemotherapy impacts the entire body, our molecular approach uses the cancer’s own biology as a homing beacon. Located in a state-of-the-art facility near the Donaukanal, Minute Medical offers this therapy in an exclusive outpatient setting, allowing patients to receive world-class nuclear medicine without the confinement of a traditional hospital ward. The science: the "Lock and Key" mechanism. The effectiveness of Lu-177 PSMA therapy relies on the overexpression of the prostate-specific membrane antigen (PSMA) on the surface of malignant cells. We utilize a specialized molecule, the ligand, that acts as a "key" designed to fit only the PSMA "locks" found on prostate cancer metastases. This ligand is chemically bound to Lutetium-177, a potent beta-emitter. Once injected, these molecules circulate through the bloodstream, bypassing healthy tissue to bind directly to tumors. Upon arrival, the Lutetium releases its energy within a tiny radius of 1–2 mm, destroying the cancer cell's DNA while leaving the surrounding healthy organs virtually untouched. The diagnostic blueprint: treat what you see at Minute Medical, we strictly follow the theranostics principle: "We treat what we see. " Before the first dose is administered, every patient undergoes a high-resolution 68Ga-PSMA PET/CT scan. This allows our nuclear medicine specialists, led by experts like Dr. Markus Hartenbach, to visualize every metastatic deposit in the body, from bone lesions to lymph nodes. Only if the PET/CT confirms high PSMA expression do we proceed with the therapy. This diagnostic certainty ensures that we offer treatment only to those most likely to show a significant biochemical response, such as a drop in PSA levels and tumor shrinkage. We have designed the treatment experience at Minute Medical to be as comfortable and "non-clinical" as possible. The administration itself is a simple intravenous infusion that lasts about 20 minutes. To protect your healthy tissues during the process, we implement a strict organ-protection protocol:Because the radiation range of Lutetium-177 is so localized, the "downtime" is minimal. Unlike traditional radiotherapy, which can cause weeks of fatigue, most of our patients report only mild tiredness for a few days. You are free to leave the clinic shortly after the infusion, with simple radiation safety guidelines to protect your family at home. A standard course usually involves three to four cycles spaced six to eight weeks apart. We monitor your progress with regular blood tests and a follow-up PET/CT after the third session to objectively assess the destruction of metastatic sites. Choosing our Vienna clinic means accessing a boutique medical experience where cutting-edge nuclear physics meets personalized care. By offering 177-Lutetium therapy on an outpatient basis, we provide a life-extending option that prioritizes your independence and quality of life. At Minute Medical, we don't just treat the disease; we provide a sophisticated, targeted path toward stabilizing your health in a setting that feels like the future of medicine.